蛋白酶体抑制剂硼替佐米联合顺铂对宫颈癌细胞增殖的影响

doi:10.6040/j.issn.1671-7554.0.2017.138

摘要/Abstract

摘要： 目的观察蛋白酶体抑制剂硼替佐米(BTZ)联合顺铂(CIS)对宫颈癌HeLa细胞增殖的影响并研究其相关机制。方法将Hela细胞分为NC组、CIS组、BTZ组、C&B组,分别以DMEM培养液、含CIS的培养液、含BTZ的培养液、含CIS及BTZ的培养液培养。以CCK-8法检测各组细胞的增殖抑制率,Western blotting法检测各组细胞中p53与Rb蛋白的表达水平,流式细胞仪检测细胞凋亡率。组间比较采用析因设计资料的方差分析。结果 C&B组细胞增殖抑制率高于其他各组(P<0.05)。CIS组及C&B组中p53表达量较高(P<0.05),BTZ组与NC组相比差异无统计学意义。与NC组相比,BTZ组Rb表达量较高(P<0.05),CIS组、C&B组与NC组相比,差异无统计学意义。流式结果示CIS和BTZ在诱导细胞凋亡方面具有交互作用。结论 CIS可能通过调控p53通路对宫颈癌HeLa细胞增殖产生抑制作用,而BTZ可能通过调控Rb通路对宫颈癌HeLa细胞增殖产生抑制作用,且BTZ与CIS联用在抑制HeLa细胞增殖方面具有协同交互作用。

关键词: 蛋白酶体抑制剂, 硼替佐米, 顺铂, p53蛋白, Rb蛋白, Hela细胞, 宫颈癌

Abstract: Objective To investigate the effects of proteasome inhibitor bortezomib(BTZ), cisplatin(CIS)and their combination on proliferation of cervical cancer cells and to explore the mechanisms involved. Methods Hela cells were divided into four groups: normal control group(NC group), BTZ group, CIS group and C&B group. Cell Counting Kit-8(CCK-8)was used to examine HeLa cell proliferation after treatment. Western blotting was used to investigate the expression of p53 protein and Rb protein in the treated cells. Flow cytometry was used to observe apoptosis ratio after treatment. Results The inhibitory effect on the proliferation of HeLa cells in the C&B group was higher compared with the other groups. Western blotting analysis showed that the expression of p53 protein in CIS group was higher than that in NC group and C&B group(P<0.05), but had no obvious difference in BTZ group. Compared with that in other three groups, the expression of Rb protein in BTZ group was higher(P<0.05), and no obvious change was observed among these three groups. Flow cytometry demonstrated a synergistic effect of BTZ and CIS on HeLa cell apoptosis. Conclusion CIS may inhibit the proliferation of HeLa cells via regulating the expression of p53; BTZ may inhibit the proliferation of HeLa cells via regulating the expression of Rb; BTZ could enhance the inhibitory effects of CIS on HeLa cells.

Key words: Proteasome inhibitor, Bortezomib, Cisplatin, p53 protein, Rb protein, Hela cell, Ceivical cancer

中图分类号:

R741.05

丁长宽,陈健行. 蛋白酶体抑制剂硼替佐米联合顺铂对宫颈癌细胞增殖的影响[J]. 山东大学学报 (医学版), 2018, 56(1): 70-75.

DING Changkuan, Jason Chen. Effects of proteasome inhibitor bortezomib combined with cisplatin on proliferation of human cervical cancer cells[J]. Journal of Shandong University (Health Sciences), 2018, 56(1): 70-75.

参考文献

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1): 7-30.
[2] Flagg EW, Schwartz R, Weinstock H. Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: potential impact of human papillomavirus vaccination[J]. Am J Public Health, 2013, 103(8): 1428-1435.
[3] Heley S. Human papillomavirus: beware the infection you cant see[J]. Aust Fam Physician, 2003, 32(5): 311-315.
[4] de Villiers EM. Cross-roads in the classification of papillomaviruses[J]. Virology, 2013, 445(1-2): 2-10.
[5] Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention[J]. Gynecol Oncol, 2008, 110(Suppl 1): 18-25.
[6] Nachajova M, Brany D, Dvorska D. Telomerase and the process of cervical carcinogenesis[J]. Tumor Biology, 2015, 36(10): 7335-7338.
[7] Kennedy EM, Kornepati AV, Goldstein M, et al. Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease[J]. J Virol, 2014, 88(20):11965-11972.
[8] Shiho O, Ning M, Raynoo T. DNA Damage in inflammation-related carcinogenesis and cancer stem cells[J]. Oxid Med Cell Longev, 2013, 2013: 387014. doi: 10.1155/2013/387014.
[9] 蒲业迪, 李丽珍,马道新,等. 硼替佐米耐药多发性骨髓瘤细胞株KM3/BTZ的建立[J]. 山东大学学报(医学版), 2013, 51(2): 33-36. PU Yedi, LI Lizhen, MA Daoxin, et al. Establishment of a bortezomib-resistant cell line KM3 /BTZ of human multiple myeloma[J].Journal of Shandong University(Health Sciences), 2013, 51(2): 33-36.
[10] 钟明星,邱帅. 硼替佐米联合地塞米松用于多发性骨髓瘤治疗的临床观察[J]. 中国医院药学杂志, 2016, 36: 292.
[11] 任金海,郭晓楠. 多发性骨髓瘤诊断与治疗的研究进展[J]. 临床荟萃, 2017, 32(2): 177-180. REN Jinhai, GUO Xiaonan. Research progress of diagnosis and treatment of multiple myeloma[J]. Clinical Fous, 2017, 32(2): 177-180.
[12] Tewari KS, Sill MW, Long HJ, et al. Improved survival with bevacizumab in advanced cervical cancer[J]. N Engl J Med, 2014, 370(8): 734-743.
[13] Virag P, Perde-Schrepler M, Fischer-Fodor E, et al. Superior cytotoxicity and DNA cross-link induction by oxaliplatin versus cisplatin at lower cellular uptake in colorectal cancer cell lines[J]. Anticancer Drugs, 2012, 23(10): 1032-1038.
[14] 刘亚飞,张奇舒,袁首道,等. HPV永生化细胞系与SiHa细胞系蛋白质表达差异的质谱分析[J]. 山东大学学报(医学版), 2015, 53(3): 22-26. LIU Yafei, ZHANG Qishu, YUAN Shoudao, et al. Mass spectrometry analysis of differentially expressed proteins between HPV immortalized cell line and SiHa cell line[J]. Journal of Shandong University(Health Sciences), 2015, 53(3): 22-26.
[15] 孙晓莉, 高美华, 王在秋, 等. HPV-DNA与TCT联合检测在宫颈癌诊断中的应用[J]. 现代生物医学进展, 2012, 12(9):1745-1747. SUN Xiaoli, GAO Meihua, WANG Zaiqiu, et al. Application of HPV-DNA detecting with TCT test in cervical carcinoma diagnosis[J]. Progress in Modern Biomedicine, 2012, 12(9): 1745-1747.
[16] Toft L, Storgaard M, Muller M, et al. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial[J]. J Infect Dis, 2014, 209(8): 1165-1173.
[17] Ljubojevic S. The human papillomavirus vaccines[J]. Acta Dermatovenerol Croat, 2006, 14(3): 208.
[18] Stillo M, Carrillo Santisteve P, Lopalco PL. Safety of human papillomavirus vaccines: a review[J]. Expert Opin Drug Saf, 2015, 14(5): 697-712.
[19] Barac YD, Emrich F, Krutzwakd-Josefson E, et al. The ubiquitin-proteasome system: a potential therapeutic target for heart failure[J]. J Heart Lung Transplant, 2017, 36(7): 708-714.
[20] Tomaic V, Pim D, Thomas M, et al. Regulation of the human papillomavirus type 18 E6/E6AP ubiquitin ligase complex by the HECT domain-containing protein EDD[J]. J Virol, 2011, 85(7): 3120-3127.
[21] Todorovic B, Hung K, Massimi P, et al. Conserved region 3 of human papillomavirus 16 E7 contributes to deregulation of the retinoblastoma tumor suppressor[J]. J Virol, 2012, 86(24): 13313-13323.
[22] Au Yeung CL, Tsang TY, Yau PL, et al. Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway[J]. Oncogene, 2011, 30(21): 2401-2410.
[23] Nevins JR. The Rb/E2F pathway and cancer[J]. Hum Mol Genet, 2001, 10(7): 699-703.
[24] Liu H, Li X, Ning G, et al. The Machado-Joseph disease deubiquitinase ataxin-3 regulates the stability and apoptotic function of p53[J]. PLoS Biol, 2016, 14(11): e2000733. doi: 10.1371/journal.pbio.2000733.
[25] Chen R, Zhang H, Liu P, et al. Gambogenic acid synergistically potentiates bortezomib-induced apoptosis in multiple myeloma[J]. J Cancer, 2017, 8(5): 839-851.
[26] Bulbul P, Andrei LG. Proteasome inhibitors induce p53-independent apoptosis in human cancer cells[J]. Am J Pathol, 2011, 178(1): 355-360.
[27] Adams J. The development of proteasome inhibitors as anticancer drugs[J]. Cancer Cell, 2004, 5(5): 417-421.
[28] Liu X, Roberts J, Dakic A, et al. HPV E7 contributes to the telomerase activity of immortalized and tumorigenic cells and augments E6-induced hTERT promoter function[J]. Virology, 2008, 375(2): 611-623.

相关文章 15

[1]	陈泉材,韩赛,刘露,孙雨,尤学武,张俊华,张友忠. CDC7、MCM4在105例宫颈病变组织中的表达及意义[J]. 山东大学学报 (医学版), 2022, 60(1): 34-39.
[2]	王璐,赵新蕊,朱琳. 25例早期宫颈癌无瘤化免举宫腹腔镜子宫切除术临床效果[J]. 山东大学学报 (医学版), 2021, 59(6): 76-80.
[3]	梁婷婷,杨勇霞,侯丛哲,黄太胜,王华丽,朱琳. PAX1基因甲基化与宫颈高级别上皮内病变及高危型HPV分型的关联性[J]. 山东大学学报 (医学版), 2021, 59(11): 48-52.
[4]	索东阳,申飞,郭皓,刘力畅,杨惠敏,杨向东. Tim-3在药物性急性肾损伤动物模型中的表达及作用机制[J]. 山东大学学报 (医学版), 2020, 1(7): 1-6.
[5]	赵明,牛杰,李芳芹,王爱红,庞秋霞,陈美霓,周丽珍,赵菊梅. 盐霉素联合顺铂对人胃癌细胞MKN-45增殖和凋亡的影响[J]. 山东大学学报（医学版）, 2017, 55(5): 31-35.
[6]	刘京康,杨建勇,孟丽华,姜洁. 血清miR-17-92簇在HPV阳性宫颈癌中的早期诊断价值[J]. 山东大学学报（医学版）, 2017, 55(5): 86-90.
[7]	孙泽雨,陈颖,林家香,刘娟,赵蔚明. 磷脂酰肌醇-4-磷酸酶II型对宫颈癌细胞增殖及凋亡的影响[J]. 山东大学学报（医学版）, 2017, 55(11): 1-6.
[8]	王雅芬,杨勇霞,刘娅,马德美,朱琳. 宫颈细胞学阴性且高危型人乳头瘤病毒阳性人群的分流方法[J]. 山东大学学报（医学版）, 2016, 54(8): 69-71.
[9]	彭慧,何君梅,苏雪莲. 血清循环miR-375检测对宫颈癌早期诊断及术后监测的意义[J]. 山东大学学报（医学版）, 2016, 54(3): 68-71.
[10]	崔勇, 张荣香, 王福立, 王国颖, 冯建林, 张海霞. BSD2000相控阵聚焦深部热疗联合TP方案化疗治疗晚期卵巢癌的临床效果[J]. 山东大学学报（医学版）, 2015, 53(7): 53-57.
[11]	刘琼, 蒲业迪, 代广霞, 马家乐, 杨建霞, 李丽珍, 李颢, 王鲁群. 硼替佐米耐药多发性骨髓瘤细胞基因表达谱分析[J]. 山东大学学报（医学版）, 2015, 53(6): 33-38.
[12]	杨璐, 刘延国, 李际盛, 王秀问. 蟾毒灵对非小细胞肺癌顺铂化疗的增敏作用及机制[J]. 山东大学学报（医学版）, 2015, 53(3): 6-11.
[13]	杜义江, 肖长义, 叶红, 汤桂成, 黎家华. CaSki细胞内HPVL1蛋白的表达[J]. 山东大学学报（医学版）, 2015, 53(3): 17-21.
[14]	贾振军, 曲勇, 张世杰. HER2和p53在胃腺癌不同衍变阶段中的表达及意义[J]. 山东大学学报（医学版）, 2015, 53(3): 73-76.
[15]	彭静, 李卉, 杜玮. 皮下注射硼替佐米的护理体会[J]. 山东大学学报（医学版）, 2014, 52(Z1): 180-181.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed